American Association for Cancer Research (AACR)
Annual Meeting
April 1-5, 2017

(Case CCC Members in BOLD)

LECTURES/PRESENTATIONS

Sanford D. Markowitz, MD, PhD
Presenter, “Genetic contributions to colon cancer: Cancer disparities in African Americans”
ED28 - Biology of Disparities with Emphasis on Prostate, Breast, and Colorectal Cancer: A Study of African Americans and Caucasians
April 1, 2017, 10:15 - 12:15 PM; Room 152 - Level 1 Washington Convention Center
Co-Leader, GI Cancer Genetics Program, Case CCC; Markowitz-Ingalls Professor of Cancer Genetics, CWRU School of Medicine; medical oncologist, UH Seidman Cancer Center
http://www.abstractsonline.com/pp8/#!/4292/session/234

Alex Huang, MD, PhD
Session Chair, MW15 – Multimodal Imaging of Tumor Microenvironment and Immune Response
April 1, 2017, 1:00 - 3:00 PM; Room 207 - Level 2 Washington Convention Center
Co-Leader, Hematopoietic and Immune Cancer Biology Program, Case CCC; Associate Professor, Pediatrics, CWRU School of Medicine; Program Director, Pediatric Hematology and Oncology, UH Cleveland Medical Center and Rainbow Babies and Children’s Hospital
http://www.abstractsonline.com/pp8/#!/4292/session/254

Mohamed Abazeed, MD, PhD
Panelist, TM06 - Radiation Science and Medicine Working Group Town Hall Meeting and Networking Reception
April 3, 2017, 5:00 - 7:00 PM Liberty Ballroom - Meeting Level 4 Marriott Marquis DC
Member, Case CCC; Associate Staff, Radiation Oncology, Cleveland Clinic; Assistant Professor, Medicine, Cleveland Clinic Lerner College of Medicine of CWRU
http://www.abstractsonline.com/pp8/#!/4292/session/108

Kishore Guda, DVM, PhD
Presenter, “The mutational landscapes of African American colon cancers”
SY53 - Minorities in Cancer Research Scientific Symposium: The Role of Diverse Populations in Precision Medicine
Zhenghe John Wang
Presenter, "Technologies for defining the cancer interactome"
NIH10 - NCI Cross-Disciplinary Programs Supporting Integrated Cancer Research
April 4, 2017, 2:45 - 4:45 PM; Marquis Ballroom Salons 3-4 - Meeting Level 2 Marriott Marquis DC
Co-Leader, GI Cancer Genetics Program, Case CCC; Professor, Genetics and Genome Sciences, CWRU School of Medicine
http://www.abstractsonline.com/pp8/#!/4292/session/886

Jeremy Rich, MD
Co-chair, MS.TB02.01 - Tumor Stem Cell Biology
April 4, 2017, 3:00 - 5:00 PM; Room 150 - Level 1 Washington Convention Center
Member, Case CCC; Co-Director, National Center for Regenerative Medicine; Staff, Stem Cell Biology and Regenerative Medicine, Cleveland Clinic; Professor, Molecular Medicine, Cleveland Clinic Lerner College of Medicine of CWRU
http://www.abstractsonline.com/pp8/#!/4292/session/577

Raffaella Spina, PhD – AACR Scholar in Training Awardee
Presenter, 5023 “Disruption of Monocarboxylate transporter-4 Basigin interaction as an effective strategy to inhibit hypoxic response, tumor growth and vascularization, and stem cell phenotype in human glioblastoma in vitro and in vivo"
Raffaella Spina1, Dillon M. Voss1, Kah Suan Lim2, Constance J. Jeffery3, Eli E. Bar1. 1Case Western Reserve Univ., Cleveland, OH; 2Dana-Farber Cancer Institute, Boston, MA; 3The University of Illinois at Chicago, Chicago, IL
MS.TB02.01 - Tumor Stem Cell Biology
April 4, 2017, 3:00 - 5:00 PM; Room 150 - Level 1 Washington Convention Center
Post-doc, Eli Bar lab, Neurological Surgery, CWRU School of Medicine
http://www.abstractsonline.com/pp8/#!/4292/session/577

CLINICAL TRIALS PRESENTATIONS

CT007 – “Tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): Final results of a randomized, multi-center, phase III trial”
Roger Stupp1, Monika E. Hegi2, Ahmed Idbaith3, David M. Steinberg4, Benoit Lhermitte2, William Read5, Steven A. Toms6, Gene H. Barnett7, Garth Nicholas8, Chae-Yong Kim9, Karen Fink10, Andrea Salmaggi11, Frank S. Lieberman12, Jay-Jiguang Zhu13, Lynne Taylor14, Giuseppe Stragliotto15, Andreas F. Hottinger2, Elon D. Kirson16, Uri Weinberg16, Yoram Palti16, Zvi Ram17, on behalf of the EF-14 trial investigators. 1University Hospital Zurich & Northwestern University, Zurich & Chicago, Switzerland; 2Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; 3Groupe Hospitalier Pitié-Salpêtrière, Paris, France; 4Tel Aviv University, Tel Aviv, Israel; 5Emory University Hospital Midtown, Atlanta,
Session CTMS01 - Breast Cancer, Ovarian Cancer, and Glioblastoma Clinical Trials
April 2, 2017, 3:05 - 3:20 PM; Ballroom C, Level 3, Washington Convention Center
http://www.abstractsonline.com/pp8/#!4292/presentation/12353

CT013 – “NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DMI) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC)”
Jame Abraham1, Shannon L. Puhalla2, William M. Sikov3, Alberto J. Montero1, Jan H. Beumer2, Marc E. Buyse4, Laura M. Adamson5, Ashok Srinivasan5, Katherine L. Pogue-Geile5, Samuel A. Jacobs5. 1NSABP, and The Cleveland Clinic, Cleveland, OH; 2NSABP, and The University of Pittsburgh Cancer Institute, Pittsburgh, PA; 3NSABP, and The Women and Infants Hospital of Rhode Island, Providence, RI; 4International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium; 5NSABP, Pittsburgh, PA
Session CTMS01 – Breast Cancer, Ovarian Cancer, and Glioblastoma Clinical Trials
April 2, 2017, 4:35 - 4:50 PM; Ballroom C, Level 3, Washington Convention Center
http://www.abstractsonline.com/pp8/#!4292/presentation/12352

CT018 – “Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial”
Roberta Zappasodi1, Yanyun Li1, Mohsen Abu-Akeel1, Jingjing Qi1, Philip Wong1, Cynthia Sirard2, Michael Postow1, David A. Scher1, Walter Newman2. Henry Koon3, Vamsidhar Velcheti4, Margaret K. Callahan1, Jedd D. Wolchok1, Taha Merghoub1. 1Memorial Sloan Kettering Cancer Center, New York, NY; 2Leap Therapeutics, Cambridge, MA; 3Case Western Reserve University, Cleveland, OH; 4Cleveland Clinic, Cleveland, OH
Session CTSY02 – Immuno-oncology Biomarkers in Clinical Trials
April 2, 2017, 3:36 - 3:55 PM; Hall D-E, Level 2, Washington Convention Center
http://www.abstractsonline.com/pp8/#!4292/presentation/12335

CT081 – “Molecular correlates of differential response to Atezolizumab +/- Bevacizumab vs Sunitinib in a Phase II study in untreated metastatic renal cell carcinoma (RCC) patients”
David McDermott1, Mahrukh Huseni2, Brian Rini3, Robert Motzer4, Michael Atkins5, Berard Escudier6, Dorothee Nickles8, Zach Boyd2, Shruthi Sampath2, Jennifer Doss2, Ning Leng2, Christina Schiff2, Daniel S. Chen2, Gregg Fine2, Thomas Powles7, Prili S. Hegde2. 1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; 2Genentech, Inc., South San Francisco, CA; 3Cleveland Clinic, Cleveland, OH; 4Memorial Sloan-Kettering Cancer Center, New York, NY; 5Georgetown University Medical Center, Washington, DC; 6Gustave Roussy, Villejuif, France; 7Bar's Cancer Institute, Queen Mary University of London, London, United Kingdom
CT132 / 13 – “A Phase 2b randomized study of selinexor in patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) demonstrates durable responses in both GCB & Non-GCB subtypes”
Marie Maerevoet1, Jason Westin2, Catherine Thieblemont3, Josee Zijlstra4, Brian T. Hill5, Fatima De La Cruz Vicente6, Sylvain Choquet7, Paolo Caimi8, Jason Kaplan9, Miguel Albenda Caanes10, John Kuruvilla11, George Follows12, Eric Van den Neste13, Julie Meade14, Brendan Wrigley14, Marissa Devlin14, Conny Nippgen14, Humphrey Gardiner14, Sharon Shacham14, Michael G. Kauffman14, Rene-Olivier Casasnovas15.1 Institute Jules Bordet, Brussels, Belgium; 2 MD Anderson, Houston, TX; 3 Hospital Saint Louis, Paris, France; 4 VU University Medical Center, Amsterdam, Netherlands; 5 Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; 6 Hospital University Virgen del Rocio, Sevilla, Spain; 7 Hospital Pitie Salpetriere, Paris, France; 8 University Hospital Seidman Cancer Center, Cleveland, OH; 9 Northwestern University Feinberg School of Medicine, Chicago, IL; 10 Hospital Universitario La Paz, Madrid, Spain; 11 Princess Margaret Hospital, Toronto, ON, Canada; 12 Cambridge University Teaching Hospitals NHS Foundation Trust, Cambridge, United Kingdom; 13 Cliniques Universitaires Saint-Luc, Brussels, Belgium; 14 Karyopharm Therapeutics, Newton, MA; 15 CHU Dijon, Dijon, France
Session PO.CT04 - Phase I-III Clinical Trials and Pediatric Clinical Trials
April 4, 2017, 1:00 - 5:00 PM; Section 33
http://www.abstractsonline.com/pp8/#!/4292/presentation/12449

LB-091 / 16 – “CpG island DNA methylation regulates alternative cleavage and polyadenylation”
Thomas Sweet, Lihua Jin, Josephine Dermawan, Angela H. Ting. The Cleveland Clinic, Cleveland, OH
Session LBPO.MCB02 - Late-Breaking Research: Molecular and Cellular Biology 2
April 3, 2017, 8:00 - 12:00 PM; Section 36
http://www.abstractsonline.com/pp8/#!/4292/presentation/12027

LB-129 / 1 – “NDAT and P-bi-TAT formulations of tetraiodothyroacetic acid (tetrac) induce devascularization, necrosis and apoptosis in glioblastoma xenografts”
Paul J. Davis1, Sudha Thangirala1, Stewart Sell2, Aleck Hercbergs3, Shaker A. Mousa1.1 Albany College of Pharmacy & Health Sciences, Rensselaer, NY; 2 Wadsworth Center, New York State Department of Health, Albany, NY; 3 Cleveland Clinic, Cleveland, OH
Session LBPO.TB01 - Late-Breaking Research: Tumor Biology 1
April 3, 2017, 1:00 - 5:00 PM; Section 36
http://www.abstractsonline.com/pp8/#!/4292/presentation/12082
LB-255 / 21 – “Prognostic role of neuroendocrine differentiation marker in prostate adenocarcinoma”
Menglei Zhu¹, Wei Chen¹, Michael Glover², Eswar Shankar², Gregory T. MacLennan², Sanjay Gupta². ¹University Hospitals Cleveland Medical Center, Cleveland, OH; ²Case Western Reserve Univ., Cleveland, OH
Session LBPO.CL02 - Late-Breaking Research: Clinical Research 2 / Endocrinology
April 4, 2017, 1:00 - 5:00 PM; Section 34
http://www.abstractsonline.com/pp8/#/4292/presentation/11864

419 / 19 – “Integrative analysis of multi-omics tumor profiles identifies pathways associated with resistance to anti-HER2 therapy in early stage breast cancer”
Salendra Singh¹, Hannah Gilmore¹, Maysa Abu-Khalaf², George Somlo³, William Sikov⁴, Lyndsay Harris⁵, Vinay Varadan¹. ¹Case Western Reserve Univ., Cleveland, OH; ²Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; ³City of Hope National Med Center, Duarte, CA; ⁴Warren Alpert Medical School of Brown University, Providence, RI; ⁵National Cancer Institute, Rockville, MD
Session PO.MCB09.01 - Genomic Screening for Cancer Dependencies and Drug Response
April 2, 2017, 1:00 - 5:00 PM; Section 17
http://www.abstractsonline.com/pp8/#/4292/presentation/6682

478 / 19 – “Regulation of cross talk between AR and Wnt/beta-catenin pathways in prostate cancer”
Alexis Plaga, Girish C. Shukla. Cleveland State University, Cleveland, OH
Session PO.MCB10.01 - MicroRNA Regulation of Cancer Biology 1
April 2, 2017, 1:00 - 5:00 PM; Section 19
http://www.abstractsonline.com/pp8/#/4292/presentation/2064

492 / 6 – “Chronic inflammation contributes to neoplastic progression in prostate tissue: a needle biopsy study”
Shardul C. Soni, Michael Glover, Qinghu Ren, Gregory T. MacLennan, Pingfu Fu, Sanjay Gupta. Case Western Reserve University
Session PO.MCB07.01 - Molecular Carcinogenesis and Chromosomal Alternations
April 2, 2017, 1:00 - 5:00 PM; Section 21
http://www.abstractsonline.com/pp8/#/4292/presentation/1162

496 / 10 – “Ubiquitin specific peptidases 37 promotes constitutive replication fork movement by stabilizing Chk1 via its deubiquitination”
Mayank Singh¹, Amy C. Burrows², Andrew Dickson², Komal Komal¹, Debjani Pal¹, Matthew K. Summers¹. ¹Ohio State University, Columbus, OH; ²Cleveland Clinic, Cleveland, OH
Session PO.MCB07.01 - Molecular Carcinogenesis and Chromosomal Alternations
April 2, 2017, 1:00 - 5:00 PM; Section 21
http://www.abstractsonline.com/pp8/#/4292/presentation/1196

882 / 13 – “Interpreting glioma MR imaging and somatic mutations in a cancer hallmark context”
John Graf1, Mirabela Rusu1, Yunxia Sui1, Dattesh Shanbhag2, Uday Patil2, Jeffrey Kiefer3, Jill Barnholtz-Sloan4, Michael Berens3, Fiona Ginty1, Sandeep Gupta1, Chinnappa Kodira1, Lee Newberg1, Sushravya Raghunath1, Anup Sood1. 1GE Global Research, Niskayuna, NY; 2GE Global Research, Bangalore, India; 3Translational Genomics Research Institute, Phoenix, AZ; 4Case Comprehensive Cancer Center, Cleveland, OH
Session PO.TB07.01 - Imaging Cancer Immunotherapy, Tumor Microenvironment, and Other Aspects of Tumor Biology
April 2, 2017, 1:00 - 5:00 PM; Section 41
http://www.abstractsonline.com/pp8/#!/4292/presentation/2469

883 / 14 – “Elucidating cancer hallmark context from glioma MR imaging and RNA expression data”
Yunxia Sui1, Mirabela Rusu1, Dattesh Shanbhag2, Uday Patil2, Jeffrey Kiefer3, Jill Barnholtz-Sloan4, Michael Berens3, Fiona Ginty1, Graf John1, Sandeep Gupta1, Chinnappa Kodira1, Lee Newberg1, Sushravya Raghunath1, Anup Sood1. 1GE Global Research, Niskayuna, NY; 2GE Global Research, Bangalore, India; 3Translational Genomics Research Institute, Phoenix, AZ; 4Case Comprehensive Cancer Center, Cleveland, OH
Session PO.TB07.01 - Imaging Cancer Immunotherapy, Tumor Microenvironment, and Other Aspects of Tumor Biology
April 2, 2017, 1:00 - 5:00 PM; Section 41
http://www.abstractsonline.com/pp8/#!/4292/presentation/2470

1080 / 3 – “Targeting the PI3K-Akt and NF-κB pathways as a combination therapy in blocking prostate cancer progression”
Eswar Shankar1, Rajnee Kanwal1, Aditi Goel1, Xiaoping Yang2, Sanjeev Shukla1, Gregory T. MacLennan1, Pingfu Fu1, Anant Madabhushi1, Parameswaran Ramakrishnan1, Sanjay Gupta1. 1Case Western Reserve Univ., Cleveland, OH; 2VA Medical Center, Cleveland, OH
Session PO.ET01.03 - Combination Therapy 1
April 3, 2017, 8:00 - 12:00 PM; Section 41
http://www.abstractsonline.com/pp8/#!/4292/presentation/6910

1289 / 20 – “Evaluation of vitamin D receptor regulated genes reveals EGFR polymorphism is associated with high-grade serous ovarian cancer in African American women”
Delores J. Grant1, Ani Manichaikul2, Lauren C. Peres2, Xin-Qun Wang2, Ann G. Schwartz3, Anna Wu4, Edward Peters5, Patricia Moorman6, Michele L. Cote7, Melissa Bondy8, Linda E. Kelemen9, Jill Barnholtz-Sloan10, Temitope O. Keku11, Cathrine Hoyo12, Andrew Berchuck6, Paul Pharoah13, Joellen M. Schildkraut13, African American Cancer Epidemiology Study (AACES) and the Ovarian Cancer Assoc Consortium (OCAC)2.
1North Carolina Central Univ., Durham, NC; 2University of Virginia, Charlottesville, VA; 3Wayne State University, Detroit, MI; 4Keck School of Medicine of USC, Los Angeles, CA; 5Louisiana State University Health Sciences, New Orleans, LA; 6Duke University Medical Center, Durham, NC; 7Wayne State University School of Medicine, Detroit, MI; 8Baylor College of Medicine, Houston, TX; 9Medical University of South Carolina, Charleston, SC; 10Case Western Reserve University School of Medicine, Cleveland, OH; 11University of
North Carolina at Chapel Hill, Chapel Hill, NC; 12North Carolina State University, Raleigh, NC; 13University of Cambridge, Cambridge, United Kingdom
Session PO.EP01.07 - Genetic Variation (Non-GWAS) and Cancer Risk, Prognosis, or Mechanisms
April 3, 2017, 8:00 - 12:00 PM; Section 11
http://www.abstractsonline.com/pp8/#/1/4292/presentation/4884

1302 / 3 – “Genome-wide association study of glioma reveals specific differences in genetic susceptibility to glioblastoma and non-glioblastoma”
Ben Kinnersley1, Beatrice S. Melin2, Jill S. Barnholtz-Sloan3, Margaret R. Wrencsch4, Christofer Johansen5, Dora Il'yasova6, Quinn Ostrom3, and members of GICC, Karim Labreche7, Jeanette E. Eckel-Passow8, Paul A. Decker8, Marianne Labussière9, Ahmed Idbaïh7, Khe Hoang-Xuan7, Anna-Luisa Di Stefano7, Karima Mokhtari7, Jean-Yves Delattre7, Pilar Galan9, Konstantinos Gousias10, Johannes Schramm10, Minouk J. Schoemaker1, Sarah J. Fleming11, Stefan Herms12, Stefanie Heilmann13, Marcus M. Nöthen13, Heinz-Erich Wichmann14, Stefan Schreiber15, Anthony Swerdlow1, Mark Lathrop16, Matthias Simon10, Marc Sanson7, Preetha Rajaraman17, Stephen Chanock17, Martha Linet17, Zhaoming Wang17, Meredith Yeager17, Rose K. Lai18, Elizabeth B. Claus19, Sara H. Olson20, Robert B. Jenkins21, Richard S. Houlston1, Melissa L. Bondy22. 1Institute of Cancer Research, Sutton, United Kingdom; 2Umeå University, Umeå, Sweden; 3Case Western Reserve University, Cleveland, OH; 4University of California, San Francisco, CA; 5Institute of Cancer Epidemiology, Copenhagen, Denmark; 6Georgia State University, Atlanta, GA; 7Institut du cerveau et de la moelle épinière (ICM), Paris, France; 8Mayo Clinic College of Medicine, Rochester, MN; 9Université Paris 13 Sorbonne Paris Cité, Paris, France; 10University of Bonn Medical Center, Bonn, Germany; 11Centre for Epidemiology and Biostatistics, University of Leeds, Leeds, United Kingdom; 12University of Basel, Basel, Switzerland; 13Institute of Human Genetics, University of Bonn, Bonn, Germany; 14Institute of Medical Informatics, Ludwig Maximilians University, Munich, Germany; 15University Clinic Schleswig-Holstein, Kiel, Germany; 16Génomé Québec, McGill University, Montreal, QC, Canada; 17National Cancer Institute, Bethesda, MD; 18Keck School of Medicine, University of Southern California, Los Angeles, CA; 19Brigham and Women’s Hospital, Boston, MA; 20Memorial Sloan Kettering Cancer Center, New York, NY; 21Mayo Clinic Comprehensive Cancer Center, Rochester, MN; 22Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
Session PO.EP01.01 - Genome-Wide Association Studies/Post-GWAS Studies
April 3, 2017, 8:00 - 12:00 PM; Section 12
http://www.abstractsonline.com/pp8/#/1/4292/presentation/2344

1315 / 16 – “Estimating sex-specific effects of genetic loci associated with glioma risk”
Quinn T. Ostrom1, Ben Kinnersley2, Margaret Wrencsch3, Jeanette E. Eckel-Passow4, Georgina Armstrong5, Terri Rice5, Yanwen Chen1, John Wiencke5, Lucie McCoy5, Helen Hansen5, Christopher Amos5, Jonine L. Bernstein7, Elizabeth B. Claus9, Dora Il'yasova9, Christoffer Johansen10, Daniel Lachance11, Rose Lai12, Ching C. Lau5, Ryan T. Merrell13, Sara H. Olson7, Siegul Sadetzki14, Joellen Schildkraut15, Sanjay Shete16, Richard S. Houlston2, Robert B. Jenkins11, Beatrice Melin17, Melissa Bondy5, Jill S. Barnholtz-Sloan1. 1Case Western Reserve University School of Medicine, Cleveland, OH; 2The Institute of Cancer Research, Sutton, United Kingdom; 3University of California, San Francisco, San
1470 / 12 - Fine-tuning the expression of heterogeneous network of genes involved in androgen signaling, aerobic glycolysis, apoptosis and epithelial-mesenchymal transition by microRNA-644a in prostate cancer potentiation of AR signaling therapy by miR-644a: Selective manipulation of the prostate cancer transcriptome by miR-644a

Jey Sabith Ebron1, Jagjit Singh1, Eswar Shankar2, Crystal M. Weyman1, Sanjay Gupta2, Daniel J. Lindner3, Girish C. Shukla1. 1Cleveland State Univ., Cleveland, OH; 2Case Western Reserve University, Cleveland, OH; 3Lerner Research Institute, Cleveland, OH

Session PO.MCB10.02 - MicroRNA Regulation of Cancer Biology 2
April 3, 2017, 8:00 - 12:00 PM; Section 18
http://www.abstractsonline.com/pp8/#/4292/presentation/2081

1581 / 7 – “Androgen receptor action in prostate cancer partitions into distinct transcriptional codes that differ in clinical relevance”

Sangeeta Kumari1, Varadha Balaji Venkadakrishnan1, Dhirodatta Senapati1, Qiang Hu2, Song Liu2, Hannelore V. Heemers1. 1Cleveland Clinic, Cleveland, OH; 2Roswell Park Cancer Institute, Buffalo, NY

Session PO.EN01.01 - Prostate Cancer Biology and Therapy
April 3, 2017, 8:00 - 12:00 PM; Section 25
http://www.abstractsonline.com/pp8/#/4292/presentation/9321

1921 / 22 – “Stem-like clusters of CD44+ circulating tumor cells seed metastases in breast cancer”

Xia Liu, Wenjing Chen, Rokana Taftaf, Huiping Liu. Case Western Reserve University

Session PO.TB02.02 - Normal and Neoplastic Stem Cells
April 3, 2017, 8:00 - 12:00 PM; Section 41
http://www.abstractsonline.com/pp8/#/4292/presentation/5937

1975 / 18 – “FAM83B: A novel regulator of cell plasticity in breast cancer”

Courtney A. Bartel, Damian J. Junk, Mark W. Jackson. Case Western Reserve University

Session PO.TB04.02 - Regulation and Imaging of Tumor Metastasis
April 3, 2017, 8:00 - 12:00 PM; Section 43
http://www.abstractsonline.com/pp8/#/4292/presentation/3499
2026 / 11 – “CHK1 inhibition synergizes with cisplatin to promote mitotic cell death via activation of caspase 2 and downregulation of E2F1 in small cell lung cancer” Wei-Hsun Hsu¹, Xiaoliang Zhao¹, In-Gyu Kim¹, Guanhua Rao¹, Justine McCutcheon¹, Shuo-Tse Hsu¹, Afshin Dowlati². Yu-Wen Zhang¹, Giuseppe Giaccone¹. ¹Georgetown Univ. Medical Ctr., Washington, DC; ²Case Western Reserve University, Cleveland, OH
Session PO.ET03.02 - Cell Death Targets
April 3, 2017, 1:00 - 5:00 PM; Section 1
http://www.abstractsonline.com/pp8/#/1/4292/presentation/7236

2117 / 14 – “TRAIL-induced apoptosis in TRAIL-resistant breast carcinoma” Jasmine M. Manouchehri, Michael Kalafatis. Cleveland State University, Cleveland, OH
Session PO.ET02.03 - Mechanism of Drug Action
April 3, 2017, 1:00 - 5:00 PM; Section
http://www.abstractsonline.com/pp8/#/1/4292/presentation/9406

2225 / 7 – “Green tea polyphenols suppress tumor growth and invasion by targeting matrix metalloproteinases, RECK and TIMP-3, in a mouse model implanted with prostate tumors” Eswar Shankar, Natarajan Bhaskaran, Rajnee Kanwal, Sanjay Gupta. Case Western Reserve University, Cleveland, OH
Session PO.PR01.04 - Molecular Targets and Cancer Prevention
April 3, 2017, 1:00 - 5:00 PM
http://www.abstractsonline.com/pp8/#/1/4292/presentation/7441

2228 / 10 – “Altering rictor with diosmetin reduces tumor progression in orthotopic prostate cancer model” Rebecca Pakradooni, Ahmad Khalifa, Riddhi Patel, Sanjeev Shukla. Case Western Reserve Univ., Cleveland, OH
Session PO.PR01.04 - Molecular Targets and Cancer Prevention
April 3, 2017, 1:00 - 5:00 PM
http://www.abstractsonline.com/pp8/#/1/4292/presentation/7444

2230 / 12 – “Luteolin selectively inhibits EZH2 and blocks H3K27 methylation in prostate cancer cells” Rajnee Kanwal¹, Xiaoping Yang², Eswar Shankar¹, Sanjeev Gupta¹. ¹Case Western Reserve Univ., Cleveland, OH; ²VA Medical Center, Cleveland, OH
Session PO.PR01.04 - Molecular Targets and Cancer Prevention
April 3, 2017, 1:00 - 5:00 PM
http://www.abstractsonline.com/pp8/#/1/4292/presentation/7446

Session PO.PR01.04 - Molecular Targets and Cancer Prevention
April 3, 2017, 1:00 - 5:00 PM
http://www.abstractsonline.com/pp8/#/1/4292/presentation/7486
2388 / 2 – “Low grade gliomas exhibit distinct patterns of epigenetic aging associated with prognostic molecular subtype"
Peter Liao, Jill Barnholtz-Sloan. Case Western Reserve University, Cleveland, OH
Session PO.MCB05.02 - Epigenetics 2
April 3, 2017, 1:00 - 5:00 PM; Section 16
http://www.abstractsonline.com/pp8/#/1/4292/presentation/8895

2444 / 1 – “Recurrent mutations and clinical outcomes in patients with follicular lymphoma”
Kilannin Krysiak¹, Cody Ramirez¹, Felicia Gomez¹, Christopher A. Miller¹, Robert S. Fulton¹, Friederike Kreisel¹, Amanda F. Cashen¹, Nancy L. Bartlett¹, Ana Ruano², Eric D. Hsi², Malachi Griffith¹, Obi L. Griffith¹, Todd A. Fehninger¹. ¹Washington University in Saint Louis, Saint Louis, MO; ²Cleveland Clinic, Cleveland, OH
Session PO.MCB09.03 - Genomic Landscape of Lymphoma, Leukemia, and Lung, Bladder, and Other Cancers
April 3, 2017, 1:00 - 5:00 PM; Section 18
http://www.abstractsonline.com/pp8/#/1/4292/presentation/6694

2531 / 10 – “Regulation of androgen signaling axis and tumor suppressive function of miR-149-5p in prostate cancer”
Savita Singh¹, Jey Sabith Ebron¹, Eswar Shankar², Sanjay Gupta², Daniel Lindner³, Girish Shukla¹. ¹Cleveland State University, Cleveland, OH; ²Case Western Reserve University & University Hospitals Case Medical Center, Cleveland, OH; ³Taussig Cancer Center, Learner Research Institute, Cleveland, OH
Session PO.MCB10.03 - MicroRNAs and Other Noncoding RNAs as Tumor Suppressors or Oncogenes
April 3, 2017, 1:00 - 5:00 PM
http://www.abstractsonline.com/pp8/#/1/4292/presentation/2106

2647 / 6 – “TGF-β type I receptor inhibitor (TEW-7197) diminishes myeloma progression by multiple immunomodulatory mechanisms in combination with ixazomib”
Byung-Gyu Kim¹, Olga Sergeeva¹, George Luo¹, Sung Hee Choi¹, Zhenghong Lee¹, Seong-Jin Kim², John Letterio¹, Ehsan Malek¹. ¹Case Western Reserve University, Cleveland, OH; ²Seoul National University, Korea, Republic of
Session PO.IM02.10 - Immune Response to Hematopoietic Tumors: New Development in Tumor Immunology
April 3, 2017, 1:00 - 5:00 PM; Section 26
http://www.abstractsonline.com/pp8/#/1/4292/presentation/6141

2835 / 8 – “Potential opposing roles of AKT isoforms in indolent versus aggressive prostate cancer”
Karina A. Miller¹, Hyun-Kyung Ko², Irwin H. Gelman¹. ¹Roswell Park Cancer Inst., Buffalo, NY; ²Cleveland Clinic, Cleveland, OH
Session PO.TB04.03 - Gene Expression in Metastatic Progression
April 3, 2017, 1:00 - 5:00 PM; Section 39
http://www.abstractsonline.com/pp8/#/1/4292/presentation/3507
2884 / 10 – “Interferon Beta (IFN-B) re-activates canonical type I IFN signaling to differentiate breast cancer stem cells (CSCs) and suppress mesenchymal/CSC driven tumor recurrence”
Mary R. Doherty¹, Damian J. Junk¹, HyeonJoo Cheon², George R. Stark², Mark W. Jackson¹. ¹CWRU, Cleveland, OH; ²Lerner Research Institute, Cleveland Clinic, Cleveland, OH
Session PO.TB02.03 - Signaling in Cancer Stem Cells
April 3, 2017, 1:00 - 5:00 PM; Section 41
http://www.abstractsonline.com/pp8/#/4292/presentation/5825

2892 / 18 – “Oncostatin M elicits cellular plasticity through cooperative STAT3-SMAD3 signaling”
Benjamin L. Bryson, Damian J. Junk, Jacob Smigiel, Neetha Parameswaran, Mary R. Doherty, Courtney A. Bartel, Mark Jackson. Case Western Reserve University, Cleveland, OH
Session PO.TB02.03 - Signaling in Cancer Stem Cells
April 3, 2017, 1:00 - 5:00 PM
http://www.abstractsonline.com/pp8/#/4292/presentation/5854

3093 / 4 – “Expression of DLL3 in metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas as potential indications for rovalpituzumab tesirine (Rova-T; SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC)”
Laura R. Saunders¹, Samuel A. Williams¹, Sheila Bhedah¹, Kumiko Isse¹, Sarah Fong¹, Marybeth A. Pysz¹, Himisha Beltran², Loredana Puca², Verena Sailer², Juan M. Mosquera², Yu Yin³, Jiaoti Huang³, Andrew J. Armstrong³, Jorge Garcia⁴, Cristina Magi-Galluzzi⁴, Vadim Koshkin⁴, Petros Grivas⁴, Farhad Kosari⁵, John Cheville⁵, Justin C. Moser⁵, Thomas J. Flotte⁵, Thorvardur Halfdanarson⁵, Aaron Mansfield⁵, Konstantinos N. Leventakos⁵, Julian R. Molina⁵, Douglas W. Ball⁶, Barry D. Nelkin⁶, Jill E. Shea⁶, Courtney L. Scaife⁶, Scott J. Dylla¹, ¹AbbVie Stemcentrx, South San Francisco, CA; ²Weill Cornell Medicine, New York, NY; ³Duke University School of Medicine, Durham, NC; ⁴Cleveland Clinic, Cleveland, OH; ⁵Mayo Clinic, Rochester, MN; ⁶Johns Hopkins, Baltimore, MD; ⁷University of Utah, Salt Lake City, UT
Session PO.ET01.02 - Drug Delivery Technology and Antibody Technology
April 4, 2017, 8:00 - 12:00 PM; Section 4
http://www.abstractsonline.com/pp8/#/4292/presentation/7029

3147 / 7 – “Comprehensive characterization of the role of T-type calcium channels in glioblastoma”
Ying Zhang¹, Nichola Cruickshanks¹, Fang Yuan¹, Baomin Wang¹, Mary Pahuski¹, Julia Wulfkohle², Isela Gallagher², Alexander F. Koeppel¹, Sarah Hatef¹, Christopher Papanicolas¹, Jeongwu Lee⁴, Eli Bar⁵, David Schiff¹, Stephen D. Turner¹, Emanuel Petricoin³, Lloyd L. Gray⁶, Roger Abouander¹. ¹Univ. of Virginia, Charlottesville, VA; ²George Mason University, Charlottesville, VA; ³George Mason University, Manassas, VA; ⁴Cleveland Clinic Lerner Research Institute, Cleveland, OH; ⁵Case Western Reserve University Neurological Surgery, Cleveland, OH; ⁶Cavion LLC, Charlottesville, VA

AACR 2017 Annual Meeting
3394 / 25 – “CGP identifies largely non-overlapping high tumor mutational burden and HRD genomic alterations in 721 clinically advanced prostate acinar adenocarcinoma cases”


Foundation Medicine, Inc., Cambridge, MA; Massachusetts General Hospital, Boston, MA; Case Western Reserve University School of Medicine, Cleveland, OH; University of California, Davis Comprehensive Cancer Center, Sacramento, CA; University of Utah School of Medicine, Salt Lake City, UT; Tufts University School of Medicine, Boston, MA

Session PO.MCB09.04 - Genomic Landscape of Breast, Prostate, Ovarian, Melanoma, and Thyroid Cancers

April 4, 2017, 8:00 - 12:00 PM; Section 16

http://www.abstractsonline.com/pp8/#/1/4292/presentation/6648

3379 / 10 – “Massively parallel sequencing analysis of breast adenomyoepitheliomas reveals the heterogeneity of the disease and identifies a subset driven by HRAS hotspot mutations”

Felipe C. Geyer, Kathleen A. Burke, Anqi Li, Anastasios D. Papanastasiou, Fresia Pareja, Anne S. Schulteis, Charlotte K. Y. Ng, Salvatore Piscuoglio, Marcia Edelweiss, Luciano G. Martelotto, Pier Selenica, Maria R. Filippo, Gabriel S. Macedo, Achim Jungbluth, Hannah Y. Wen, Juan Palazzo, Zsuzsanna Varga, Emad Rakha, Ian O. Ellis, Brian Rubin. Memorial Sloan Kettering Cancer Center, New York, NY; Thomas Jefferson University Hospital, Philadelphia, Philadelphia, PA; University Hospital Zurich, Zurich, Switzerland; Nottingham University Hospitals, Nottingham, United Kingdom; Cleveland Clinic, Cleveland, OH

Session PO.MCB09.04 - Genomic Landscape of Breast, Prostate, Ovarian, Melanoma, and Thyroid Cancers

April 4, 2017, 8:00 - 12:00 PM; Section 16

http://www.abstractsonline.com/pp8/#/1/4292/presentation/6633

3520 / 13 – “PBRM1 inactivation in renal cell cancer alters master transcription factor hub composition to repress instead of activate epithelial-differentiation”

Xiaorong Gu, Francis Enane, Reda Mahfouz, Tomas Radivoyevitch, Bartlomiej Przychodzen, Yvonne Parker, Daniel Lindner, Brian Rini, Yogen Saunthararajah. Cleveland Clinic, Cleveland, OH

Session PO.MCB04.03 - Oncogenic Transcription Factors

April 4, 2017, 8:00 - 12:00 PM; Section 21

http://www.abstractsonline.com/pp8/#/1/4292/presentation/7062

3551 / 14 – “Targeting glutamine addiction of PIK3CA mutant colorectal cancers”

Yiqing Zhao. Case Western Reserve Univ., Cleveland, OH
3625 / 24 – “Thyroid hormone, thyroxine, promotes cell proliferation and β-catenin activation in colorectal cancer”
Yee-Shin Lee1, Meng-Ti Hsieh1, Yu-Tang Chin2, Aleck Hercbergs3, Paul J. Davis4, Han-Chung Wu5, Hung-Yun Lin1. 1Taipei Medical University and Academia Sinica, Taipei, Taiwan; 2Wan-Fang Medical Center, Taipei Medical University, Taipei, Taiwan; 3The Cleveland Clinic, Cleveland, OH; 4Albany College of Pharmacy and Health Sciences, Albany, NY; 5Academia Sinica, Taipei, Taiwan
Session PO.MCB08.04 - Regulation of Metabolic Pathways in Cancer
April 4, 2017, 8:00 - 12:00 PM; Section 22
http://www.abstractsonline.com/pp8/#/1/4292/presentation/3091

3826 / 22 – “Clinical validation of a serum protein panel (FLNA, FLNB and KRT19) for diagnosis and prognosis of prostate cancer”
Shobha Ravipaty1, Wenfang Wu1, Aditee Dalvi1, Nikunj Tanna1, Joe Andreazi1, Tracey Friss1, Allisson Klotz1, Chenchen Liao1, Jeonifer Garren1, Sally Schofield1, Eleftherios P. Diamandis2, Eric A. Klein3, Albert Dobi4, Shiv Srivastava5, Poornima Tekumalla1, Michael A. Kiebish1, Vivek K. Vishnudas1, Rangaprasad Sarangarajan1, Niven R. Narain1, Viatcheslav Akmaev1. 1BERG, LLC, Framingham, MA; 2Mount Sinai Hospital, Toronto, ON, Canada; 3Cleveland Clinic, Cleveland, OH; 4Uniformed Services University of the Health Sciences and the Walter Reed Medical Center, Framingham, MA; 5Uniformed Services University of the Health Sciences and the Walter Reed Military Medical Center, Bethesda, MD
Session PO.EN01.02 - Nuclear Receptors and Endocrine Oncology Therapies
April 4, 2017, 8:00 - 12:00 PM; Section 25
http://www.abstractsonline.com/pp8/#/1/4292/presentation/2283

4173 / 26 – “Drug target mutations as a mechanism of acquired resistance to small molecules activators of protein phosphatase 2a”
Rita Tohme1, Jaya Sangodkar2, Janna Kisler1, Daniel Leonard1, Caitlin O’Connor1, Sai Gandhe1, Wenqing Xu3, David Brautigan4, Mark Chance1, Michael Ohlmeyer2, Goutham Narla1. 1Case Western Reserve University, Cleveland, OH; 2Icahn School of Medicine at Mount Sinai, New York, NY; 3University of Washington, Seattle, WA; 4University of Virginia, Charlottesville, VA
Session PO.CL10.11 - Predictive Biomarkers 3
April 4, 2017, 8:00 - 12:00 PM; Section 32
http://www.abstractsonline.com/pp8/#/1/4292/presentation/1666

4490 / 23 – “Post-transcriptional regulation on PIAS3 expression in malignant mesothelioma”
Tian He, Karen McColl, Nneha Sakre, Gary Wildey, Afshin Dowlati. Case Western Reserve University, Cleveland, OH
Session PO.MCB04.04 - Post-transcriptional and Translational Regulation in Cancer
April 4, 2017, 1:00 - 5:00 PM
4533 / 7 – “In silico analysis of enhanced radiosensitivity in radiation treatment combined with androgen deprivation therapy for prostate cancer”
Mengdi Qian1, Alexandru Almasan2, Evren Gürkan-Çavusoglu1. 1Case Western Reserve Univ., Cleveland, OH; 2Cleveland Clinic, Cleveland, OH
Session PO.BSB01.05 - Modeling and Algorithms
April 4, 2017, 1:00 - 5:00 PM; Section 24
http://www.abstractsonline.com/pp8/#/4292/presentation/4358

4618 / 3 – “TGF-B upregulates GSK3B and mediates NK dysfunction in cancer”
Evelyn Ojo, Folashade Otegbeye, Stephen Moreton, David Wald. Case Western Reserve University, Cleveland, OH
Session PO.IM01.02 - Innate Immune Response to Cancer
April 4, 2017, 1:00 - 5:00 PM
http://www.abstractsonline.com/pp8/#/4292/presentation/3253

4839 / 1 – “Ephrin-A ligands regulate cutaneous tumor etiology and metastasis through cell autonomous and non-autonomous mechanisms”
Ji Zheng1, Bethany Perez White2, Nihal Kaplan2, Zhe Zhao1, Miroslav Blumenberg3, Spiro Getsios2, Bingcheng Wang1. 1Case Western Reserve Univ., Cleveland, OH; 2Northwestern University, Chicago, IL; 3Uew York Univeristy, New York, NY
Session PO.TB04.05 - Metastasis Suppressors and Promoters
April 4, 2017, 1:00 - 5:00 PM; Section 41
http://www.abstractsonline.com/pp8/#/4292/presentation/3522

4898 / 7 – “eIF4E reshapes the surface of migrating AML cells through regulating Hyaluronic Acid synthesis & CD44 expression”
Hiba Zahreddine1, Biljana Kraljacic-Culjkovic1, Valbona Cali2, Mark Lauer2, Lucy Skrabanek2, Nabilah Khan4, Ronald Midura2, Leandro Cerchietti3, Vincent Hascall2, Craig Jordan5. 1Institute for Research in Immunology and Cancer, University of Montreal, Montreal, QC, Canada; 2Cleveland Clinic, Cleveland, OH; 3Cornell University, New York, NY; 4University of Denver, Colorado, CO; 5University of Denver, Denver, CO
Session PO.TB04.07 - Therapeutic Intervention of Cancer and Metastasis
April 4, 2017, 1:00 - 5:00 PM; Section 43
http://www.abstractsonline.com/pp8/#/4292/presentation/3565

5152 / 24 – “Cancer stem cell targeted exosomes for the treatment of metastatic breast cancer”
Golam Kibria1, Katelyn E. Lee1, Erika K. Ramos1, Simo Huang1, Clifford V. Harding1, Jan Lötval1, Huiping Liu1. 1Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH; 2Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, University of Gothenburg, Gothenburg, Sweden
Session PO.ET01.07 - Novel Drug Delivery Technology
April 5, 2017, 8:00 - 12:00 PM
http://www.abstractsonline.com/pp8/#/4292/presentation/7005
5213 / 1 – “Aberrant tumor metabolism enables GR takeover in enzalutamide-resistant prostate cancer”
Jianneng Li. The Cleveland Clinic Lerner Research Inst., Cleveland, OH
Session PO.ET04.02 - Transport and Metabolism
April 5, 2017, 8:00 - 12:00 PM; Section 8
http://www.abstractsonline.com/pp8/#/4292/presentation/5524

5230 / 10 – “Targeting two unique end-insertion G-quadruplexes formed in the 3'-end of the PDGFR-ß core promoter nuclease hypersensitive element with ellipticine analog”
Buket Onel1, Prashansa Agrawal2, Megan Carver1, Laurence H. Hurley3, Danzhou Yang1.
1Purdue University, West Lafayette, IN; 2Case Western Reserve University, Cleveland, OH; 3University of Arizona, Tucson, AZ
Session PO.CH02.01 - Chemical Biology and Structure Biology Approach to Study Cancers
April 5, 2017, 8:00 - 12:00 PM; Section 9
http://www.abstractsonline.com/pp8/#/4292/presentation/4490

5458 / 2 – “Oncostatin M induces epithelial-mesenchymal transition and stem cell properties in senescent human mammary epithelial cells”
Benjamin L. Bryson, Damian J. Junk, Mark W. Jackson. Case Western Reserve University, Cleveland, OH
Session PO.MCB11.02 - Oxidative Stress, Autophagy, and Senescence
April 5, 2017, 8:00 - 12:00 PM
http://www.abstractsonline.com/pp8/#/4292/presentation/7320

5495 / 9 – “GANT61-induced cell death involves inhibition of transcription and DNA licensing at GLI sites in the promoters of GLI-dependent target genes in human colon carcinoma cells”
Ruowen Zhang1, Jiahui Wu2, Sylvain Ferrandon2, Katie J. Glowacki1, Janet A. Houghton1.
1Southern Research Institute, Birmingham, AL; 2Cleveland Clinic, Cleveland, OH
Session PO.MCB04.05 - Regulation of Oncogenic Transcription
April 5, 2017, 8:00 - 12:00 PM; Section 2
http://www.abstractsonline.com/pp8/#/4292/presentation/6871

5599 / 1 – “Soluble PD-L1 as a surrogate biomarker of metastatic progression and resistance to antiangiogenic therapy”
Michalis Mastri1, Amanda Tracz1, Yuhao Shi2, Georg Bjarnason3, Tran Nguyen2, Brian Rini4, John M.L. Ebos1. 1Roswell Park Cancer Institute, Buffalo, NY; 2State University of New York, University at Buffalo, Buffalo, NY; 3University of Toronto, Toronto, ON, Canada; 4Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Session PO.IM02.12 - Immune Checkpoints and Immunosurveillance
April 5, 2017, 8:00 - 12:00 PM; Section 25
http://www.abstractsonline.com/pp8/#/4292/presentation/6217

5657 / 11 – “Objective measurement and significance of VISTA (PD-1H) expression in non-small cell lung cancer (NSCLC)”
Franz Villarroel-Espindola¹, Ila J. Datar¹, Vamsidhar Velcheti², David L. Rimm¹, Roy S. Herbst³, Kurt A. Schalper¹. ¹Yale School of Medicine, New Haven, CT; ²Cleveland Clinic, Cleveland, OH; ³Medical Oncology Yale Cancer Center, New Haven, CT

Session PO.CL06.02 - Innate Immunity to Generate Adaptive Immunity
April 5, 2017, 8:00 - 12:00 PM; Section 28
http://www.abstractsonline.com/pp8/#/4292/presentation/6019

5708 / 2 - “HOXA4 and HOXB3 gene expression signature as a biomarker of tumor recurrence in patients with high-grade serous ovarian cancer (HGSOC) following primary cytoreductive surgery and first-line adjuvant chemotherapy”

Jai N. Patel¹, Katherine Miller¹, James Symanowski¹, Jalid Sehouli², Chad Michener³, Ioana Braicu², Darla Destephanis¹, Ashley P. Sutker¹, Eric J. Norris¹, David Tait¹, Wendell Jones⁴, Qing Zhang¹, Chad Livasy⁵, Charles Biscotti³, Ram N. Ganapathi¹, Mahrukh K. Ganapathi¹. ¹Levine Cancer Institute, Charlotte, NC; ²Charite Medical University of Berlin, Berlin, Germany; ³Cleveland Clinic, Cleveland, OH; ⁴EA Genomics, Morrisville, NC; ⁵Carolinas HealthCare System, Charlotte, NC

Session PO.CL10.10 - Prognostic Biomarkers 2
April 5, 2017, 8:00 - 12:00 PM; Section 30
http://www.abstractsonline.com/pp8/#/4292/presentation/1461